Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

BACKGROUND: Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. METHODS: Here we describe the rationale and design of the P...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Neurol
Main Authors: Adams, David, Suhr, Ole B., Dyck, Peter J., Litchy, William J., Leahy, Raina G., Chen, Jihong, Gollob, Jared, Coelho, Teresa
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5594468/
https://ncbi.nlm.nih.gov/pubmed/28893208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-017-0948-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados